• Ophthalmic organizations request FDA reconsider moxifloxacin removal from 503B bulk list

    1 month ago - By Healio

    Several major ophthalmic organizations requested the FDA reconsider its intention to remove moxifloxacin from the 503B bulk drug list, which identifies drug substances for which there is a clinical need.
    The American Academy of Ophthalmology, the American Society of Cataract and Refractive Surgery, the American Glaucoma Society, the American Association for Pediatric Ophthalmology and Strabismus, the American Society of Retina Specialists, the Retina Society, the Macula Society and the Cornea Society formally requested the FDA retain moxifloxacin as Category 1 for 503B outsourcing facility
    Read more ...